Digipath
CHM Cannabis
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Drugdoctor, dr_lowenstein, NASDAQ2020, IB_, namtae, Chasing
Search This Board: 
Last Post: 12/14/2018 2:08:42 PM - Followers: 849 - Board type: Free - Posts Today: 41

Elite Pharmaceuticals, Inc. (ELTP)

 
\

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company developing a pipeline of proprietary pharmacological abuse-deterrent opioid products and niche generic products. Elite specializes in oral sustained and controlled release drug products with high barriers to entry. Elite owns generic which have been licensed to TAGI Pharma, Epic Pharma, Dr. Reddy’s Laboratories and Glenmark Pharmaceuticals Inc., USA.

Elite currently has eight commercial products currently being sold, six products filed with the FDA, additional approved products pending manufacturing site transfer and the NDA filing for SequestOx™.

Elite’s pipeline products include abuse-deterrent opioids utilizing the Company’s patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse.


Located in Northvale, New Jersey, Elite operates a 55,000 square foot campus under Current Good Manufacturing Practice (“cGMP”) and is a United States Drug Enforcement Agency (“DEA”) registered facility for research, development, manufacturing and packaging of pharmaceutical products.
 

About Elite's Abuse Deterrent Technology

Elite's abuse deterrent products utilize the Company's proprietary pharmacological abuse deterrent technology. Elite's abuse deterrent technology is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist. Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers.
\
 
Elite continues to expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has four US patents, one European patent, and two Canadian patents issued in this area with additional patents pending in the U.S., Canada and Europe.

More information including Elite’s proprietary Abuse Resistant Technology can be found at http://www.elitepharma.com
 

Products & Pipeline
 
Screen%20Shot%202017-05-28%20at%2011.53.29%20AM.png
 
Elite’s principle product is SequestOx™,  an immediate-release oxycodone with sequestered naltrexone abuse-deterrent opioid product for the management of moderate to severe acute pain. Additional products include bariatric, cardiovascular, antihistamine, skeletal muscle relaxants, antipsychotic, tricyclic antidepressant, along with a number of approved products pending manufacturing site transfer.
 
Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma, Dr. Reddy's Laboratories and Valeant Pharmaceuticals International. Additional information regarding Elite’s wholly owned products, partnerships, and contract manufacturing can be found at  http://www.elitepharma.com/products
\
\The list of pipeline products can be found at http://www.elitepharma.com/pipeline-generics
 
Leadership
 
Nasrat Hakim, Chairman, President & Chief Executive Officer
 
Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership.  Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company. 

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.
 

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: 
dianne@elitepharma.com

Corporate Headquarters
165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755


 

Miscellaneous Links:
 
Elite Pharmaceuticals News
http://ir.elitepharma.com/press_releases
 
SEC Filings
http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov
https://www.clinicaltrials.gov/
 
Yahoo Finance
https://finance.yahoo.com/quote/ELTP/?p=ELTP
 
Seeking Alpha
https://seekingalpha.com/symbol/ELTP
 

_ELTP Daily Chart_
    <img data-cke-saved-src="blob:https://investorshub.advfn.com/82b64db3-d95d-4da2-a29b-5de8e3a31a28"="" rel="nofollow" target="_blank">;


Digipath
CHM Cannabis
ELTP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP News: Current Report Filing (8-k) 12/10/2018 04:02:19 PM
ELTP News: Current Report Filing (8-k) 11/20/2018 04:08:02 PM
ELTP News: Current Report Filing (8-k) 11/09/2018 05:02:48 PM
ELTP News: Quarterly Report (10-q) 11/09/2018 04:38:31 PM
ELTP News: Current Report Filing (8-k) 11/05/2018 04:08:14 PM
PlusOneCoin Top Posts
#305007   LOL, namtae…nope. That is incorrect. reaper247 11/30/18 10:10:00 PM
#305587  Restored Pfffttt, namtae… reaper247 12/07/18 03:10:28 AM
#305750   Bwahaha, lowenstein… reaper247 12/10/18 12:28:06 AM
PostSubject
#305765  Sticky Note ***** Elite Pharmaceuticals and SunGen Pharma Receive FDA aELmTPa 12/10/18 07:40:22 AM
#303967  Sticky Note Wishfull thinking , elite will need another 100 Dr_Thorfin 11/19/18 08:43:48 AM
#303648  Sticky Note Within just the next 3 months: aELmTPa 11/14/18 10:36:36 PM
#302013  Sticky Note "Within 12 months, stock will be at $1 IB_ 10/17/18 06:44:01 PM
#300504  Sticky Note Abuse-Deterrent Opioids: A Business Answer To The Opioid NASDAQ2020 09/17/18 09:33:36 AM
#274770  Sticky Note memorable "calls" for elite pharma: dr_lowenstein 10/24/17 04:09:11 PM
#185967  Sticky Note The only topic here is ELTP. IH Dan (Retired) 02/23/16 09:32:46 PM
#306343   Destiny, Ditto, race to the doors! snupoled 12/14/18 02:08:42 PM
#306342   No!!!!!!No!!!!!!No!!!!!!! Why does this keep happening to me. Destiny Defined 12/14/18 02:00:55 PM
#306341   Afternoon update - Elite LOSSES GROW DOWN 4% namtae 12/14/18 01:48:14 PM
#306340   BUY BUY BUYBUY BUY rocioyogi 12/14/18 01:33:33 PM
#306338   I don’t think they are negotiating to get jour_trader 12/14/18 01:23:48 PM
#306335   Good idea namtae 12/14/18 12:47:19 PM
#306334   Really? Crap....I better sell all of my Elite Destiny Defined 12/14/18 12:44:28 PM
#306333   Yeah that's the question I've been debating as well. aELmTPa 12/14/18 12:18:34 PM
#306332   Epic retains distribution rights until the end of jour_trader 12/14/18 11:49:52 AM
#306331   nah that is wrong dr_lowenstein 12/14/18 11:44:31 AM
#306330   So in searching I find - ARbigguy1 12/14/18 11:42:31 AM
#306329   Morning Update ELITE DOWN 3% namtae 12/14/18 11:36:39 AM
#306328   nah, they are puny dr_lowenstein 12/14/18 11:35:06 AM
#306327   0.083515 ? -0.004235 SERIOUSLY?? 0.xxxxx six decimal places. ARbigguy1 12/14/18 11:02:11 AM
#306326   People want to see earnings from these appoved newguy11 12/14/18 10:57:07 AM
#306325   I am not sure if the SOX and hyder 12/14/18 10:50:25 AM
#306324   Elites made its big run from 8 cents namtae 12/14/18 10:40:59 AM
#306323   Since milestone is not refundable, what is there imanjen13 12/14/18 10:03:20 AM
#306321   Oops Ceo HAS NOT converted anything End of Class.. newguy11 12/14/18 09:15:01 AM
#306320   Thanks (i) the date that shareholder approval is obtained namtae 12/14/18 09:13:22 AM
#306319   WRONG!!!! (i) the date that shareholder approval is obtained aELmTPa 12/14/18 09:10:51 AM
#306318   WRONG AGAIN!! namtae 12/14/18 08:48:21 AM
#306317   Sorry but as the premise of the topic namtae 12/14/18 08:47:49 AM
#306316   That's what the FDA required. aELmTPa 12/14/18 05:41:24 AM
#306315   Milestone payment is NON-refundable. aELmTPa 12/14/18 05:34:47 AM
#306314   Yeah it's a mystery..............because Nasrat only stated it aELmTPa 12/14/18 05:33:41 AM
#306313   Yes. Epic will be paying for it. aELmTPa 12/14/18 05:32:10 AM
#306312   That would be the dumbest decision ever and aELmTPa 12/14/18 05:30:18 AM
#306311   He can't even convert his shares until April aELmTPa 12/14/18 05:27:35 AM
#306310   I agree. SequestOx will definitely make history. That YJ4LIFE 12/14/18 03:41:46 AM
#306309   I think so too. With all the approvals YJ4LIFE 12/14/18 03:39:09 AM
#306308   I’m with you on this one Nasdaq. $2 YJ4LIFE 12/14/18 03:37:17 AM
#306307   LOL, Lowenstein... reaper247 12/14/18 02:43:12 AM
#306306   That is fantastic information. reaper247 12/14/18 01:58:09 AM
#306305   Without proof of a lawsuit theres no need newguy11 12/14/18 01:25:17 AM
#306304   Epic kind of screwed up in not one, Jimmy Joe 12/14/18 12:40:28 AM
#306303   Prove it, unmitigated proof please LOL dr_lowenstein 12/14/18 12:01:48 AM
#306302   Hoever, it does raise an interesting question: How no2koolaid 12/13/18 11:59:37 PM
#306301   I never said there was. Now, having said dr_lowenstein 12/13/18 11:53:31 PM
#306300   Actually, the process requires a plaintiff brings the no2koolaid 12/13/18 11:48:28 PM
#306299   prove it dr_lowenstein 12/13/18 11:42:24 PM
#306298   Elite has no lawsuits filed against it.. newguy11 12/13/18 11:33:14 PM
#306297   well, to be precise, there are lots of dr_lowenstein 12/13/18 10:57:39 PM
#306296   There's no judge because there's no lawsuits newguy11 12/13/18 10:50:53 PM
#306295   OK, so what? I never claimed otherwise. By dr_lowenstein 12/13/18 10:43:41 PM
#306294   N2K, are you telling me that Elite gets no2koolaid 12/13/18 10:41:35 PM
#306292   LOL thanks for that, I never said otherwise. dr_lowenstein 12/13/18 10:29:49 PM
#306291   Just in case... no2koolaid 12/13/18 10:27:45 PM
#306290   i am reminded of something funny. The elite dr_lowenstein 12/13/18 10:23:21 PM
#306287   did I say that? no I did not dr_lowenstein 12/13/18 10:04:18 PM
PostSubject